** Shares of Ocular Therapeutix OCUL.O rise 13.5% to $14.28 in premarket trading

** OCUL says its plans to submit a marketing application for its experimental eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026

** Wet AMD is a leading cause of vision loss in older adults, marked by abnormal blood vessel growth in the retina

** Company says the study is designed to show superiority over Regeneron Pharma's REGN.O Eylea and aligns with recent FDA guidance that a single, well-controlled trial may support approval

** As of last close, stock up 47.3% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))